

## Press release

## SHL announces change in management

**Tel Aviv / Zurich, 26 October 2016** – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) ("SHL"), a leading provider and developer of advanced personal telemedicine solutions, today announced that Irit Alroy, Chief Technology Officer, will leave the company by mid January 2017. A replacement will be announced in due time.

Irit Alroy has served as SHL's Executive Vice-President and Chief Technology Officer since the company's inception. Yuval Shaked, CEO of SHL, commented: "SHL has become a leading player in the telemedicine market thanks to the seamless integration of end-user devices with a flexible and reliable IT backbone and proprietary software. Irit's leadership and know-how contributed to SHL ability to grow into such a strong position. Going forward, we intend to continue and leverage our IT and software capabilities for additional territories and new service offerings. I thank Irit for her long and dedicated service to SHL and wish her all the best for the future".

## For further information, please contact:

Martin Meier-Pfister, IRF Communications, phone: +41 43 244 81 40, shl@irfcom.ch

## **About SHL Telemedicine**

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit the web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.